Ambroxol to Slow Progression in Parkinson Disease (ASPro-PD)

Ambroxol to Slow Progression in Parkinson Disease: A Phase IIIa Multi-centre Randomised Placebo-controlled Trial

This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.

Study Overview

• Status: Recruiting
• Conditions: Parkinson Disease
• Intervention / Treatment: Drug: Placebo; Drug: Ambroxol Hydrochloride (420mg)

Detailed Description

This is a 104-week, randomized, double-blind, multi-centre, parallel group, placebo-controlled clinical trial of ambroxol hydrochloride in patients with PD, with a 26-week open-label extension phase. Participants will undergo screening to evaluate their eligibility to participate in the trial. All eligible participants will be randomised to receive either ambroxol hydrochloride (420mg) or it's matching placebo in a 1:1 ratio three times a day for 104 weeks, including a 2-week dose escalation period. Once the end of the blinded treatment has been reached, all participants will enter the open-label extension phase and will receive ambroxol hydrochloride (420mg) three times a day for 26 weeks, including a 2-week dose escalation period. All clinical staff, study investigators, and participants will be blinded to study assignments throughout the entirety of the trial.

There will be an optional sub-study including 106 participants in which a cerebrospinal fluid (CSF) sample will be taken on two occasions via a Lumbar Puncture procedure to measure ambroxol drug levels, assess whether the glucocerebrosidase enzyme has been stimulated and the levels of other substances thought to be associated with the development of PD and confirm whether the study drug has penetrated the cerebrospinal fluid and Central Nervous System.

• Study Type: Interventional
• Enrollment (Estimated): 330
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Felicia Ikeji; Phone Number: 02076799506; Email: f.ikeji@ucl.ac.uk
• Study Contact Backup: Name: ASPro-PD Trial Team; Phone Number: 02031084908; Email: cctu.aspro-pd@ucl.ac.uk

Study Locations

• United Kingdom
  • Birmingham, United Kingdom
    • Not yet recruiting
    • University Hospitals Birmingham
    • Contact: Ben Wright
    • Principal Investigator: Ben Wright, Dr
  • Bristol, United Kingdom
    • Not yet recruiting
    • Southmead Hospital Bristol
    • Contact: Alan Whone
    • Principal Investigator: Alan Whone, Dr
  • Cambridge, United Kingdom
    • Not yet recruiting
    • Addenbrookes NHS Trust
    • Contact: Caroline Williams-Gray
    • Principal Investigator: Caroline Williams-Gray, Dr
  • Edinburgh, United Kingdom
    • Not yet recruiting
    • Western General Hospital
    • Contact: David Breen
    • Principal Investigator: David Breen, Dr
  • London, United Kingdom
    • Not yet recruiting
    • Royal London Hospital
    • Contact: Alastair Noyce
    • Principal Investigator: Alastair Noyce, Prof.
  • London, United Kingdom
    • Not yet recruiting
    • Kings College London
    • Contact: Ray Chaudhuri
    • Principal Investigator: Ray Chaudhuri, Prof.
  • London, United Kingdom
    • Recruiting
    • University College London Hospital's
    • Contact: Marco Toffoli
    • Principal Investigator: Marco Toffoli, Dr
  • Newcastle, United Kingdom
    • Not yet recruiting
    • Newcastle
    • Contact: Nicola Pavese
    • Principal Investigator: Nicola Pavese, Prof.
  • Newcastle Upon Tyne, United Kingdom
    • Not yet recruiting
    • Northumbria
    • Contact: James Fisher
    • Principal Investigator: James Fisher, Dr
  • Oxford, United Kingdom
    • Not yet recruiting
    • The John Radcliffe Hospital
    • Contact: Michele Hu
    • Principal Investigator: Michele Hu, Prof.
  • Plymouth, United Kingdom
    • Recruiting
    • Derriford Hospital
    • Contact: Stephen Mullin
    • Principal Investigator: Stephen Mullin, Dr
  • Salford, United Kingdom
    • Recruiting
    • Salford Royal Hospital
    • Contact: Monty Silverdale
    • Principal Investigator: Monty Silverdale, Prof.
  • Salford, United Kingdom
    • Not yet recruiting
    • Fairfield General Hospital
    • Contact: Robert Irving
    • Principal Investigator: Robert Irving, Dr
  • Southampton, United Kingdom
    • Not yet recruiting
    • Southampton General Hospital
    • Contact: Boyd Ghosh
    • Principal Investigator: Boyd Ghosh, Dr
  • Wales, United Kingdom
    • Not yet recruiting
    • Prince Philip Hospital
    • Contact: Mark Sheehan
    • Principal Investigator: Mark Sheehan, Dr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. A diagnosis of Parkinson's disease (in accordance with the MDS diagnostic criteria) within 7 years of the screening visit confirmed by year of diagnosis.
2. Adults aged ≥ 35 and ≤ 75 years.
3. Hoehn and Yahr stage between 1-2.5, inclusive (in ON stage) at screening visit.
4. Known glucocerebrosidase gene (GBA1) status, positive or negative (status MUST be confirmed prior to screening).
5. On stable dopaminergic treatment for at least 3 months before enrolment.
6. Able and willing to provide informed consent prior to any study related assessments and/or procedures.
7. Able and willing to attend trial visits and comply with all study procedures for the duration of the trial.
8. Willing and able to self-administer oral ambroxol medication or placebo.

Exclusion Criteria:

1. Participation in another interventional clinical trial of an Investigational Medicinal Product (IMP) and use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment.
2. Use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment.
3. Participation in another clinical trial of an Investigational New Drug being tested for PD disease modifying potential within 12 months prior to the first dose of trial treatment.
4. Past surgical history of deep brain stimulation.
5. Use of ambroxol in the past 12 months.
6. Exposure to Exenatide within 12 months prior to the first dose in this current trial.
7. Concomitant medications that in the opinion of the Investigator would preclude participation in the study e.g., exenatide or other GLP1 agonist for diabetes.
8. Confirmed dysphagia that would preclude self-administration of ambroxol.
9. History of known sensitivity to the study medication, ambroxol or its excipients (lactose monohydrate, granulated microcrystalline cellulose, copovidone and magnesium stearate) in the opinion of the investigator that contraindicates their participation.
10. History of known rare hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
11. Presence of the LRRK2 G2019S mutation (status to be confirmed prior to screening).
12. History of drug abuse or alcoholism in the opinion of the Investigator that would preclude participation in the trial.
13. Pregnant (or planned pregnancy during the trial) and/or breastfeeding.
14. Women of childbearing potential (WOCBP) and male participants with a partner of childbearing potential not willing to use highly effective contraception or abstinence for the duration of the trial treatment and for 2 weeks following the last dose of the study drug.

15. Any clinically significant or unstable medical or surgical condition that in the opinion of the Investigator may; put the participant at risk when participating in the study, influence the results of the study or affect the participants ability to take part in the study, as determined by medical history, physical examinations, electrocardiogram (ECG) or laboratory tests. Such conditions may include:

    A. Impaired renal function with creatinine clearance <50ml/min at screening visit.

    B. Moderate/Severe hepatic impairment.

    C. A major cardiovascular event (e.g., myocardial infarction, acute coronary syndrome, compensated congestive heart failure, pulmonary embolism, coronary revascularisation) that occurred within 6 months prior to the screening visit.

16. Severe depression defined by a score >20 on the Beck Depression Inventory-II (BDI-II) at screening.
17. Significant cognitive impairment defined by a score <20 on the Montreal Cognitive Assessment (MoCA) at screening.
18. Use of trihexyphenidyl or benztropine within 30 days prior to the first dose of trial treatment.
19. Only applicable for those patients consenting to the optional CSF sub-study: Evidence or history of hypersensitivity to lidocaine or its derivatives.
20. Only applicable for those patients consenting to the optional CSF sub-study: current treatment with anti-coagulants (e.g., warfarin) that might preclude safe completion of the lumbar puncture in the opinion of the Investigator. Aspirin will be permitted.
21. Only applicable for those patients consenting to the optional CSF sub-study: Significant known lower spinal malformations or other spinal abnormalities that would preclude a lumbar puncture.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Ambroxol hydrochloride; Participants will receive ambroxol hydrochloride (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase. n=165	Drug: Ambroxol Hydrochloride (420mg); Oral tablet; Other Names: Ambroxol
Placebo Comparator: Placebo; Participants will receive ambroxol hydrochloride matching placebo (tablets) for 104 weeks (blinded treatment period). Participants will receive ambroxol hydrochloride matching placebo 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the blinded treatment period. Participants will then enter the open-label extension and will receive ambroxol hydrochloride 420mg daily for Days 1-5, then 840mg daily for Days 6-10, then 1260mg for the remainder of the open-label extension phase. n=165	Drug: Placebo; Oral tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- III score from baseline to Week 104.	The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Comparison of MDS-UPDRS Parts I-III total score at 104 weeks between participants according to treatment allocation will be made. Parts I and II are measured in the practically defined ON medication state and Part III is measured in the practically defined OFF medication state. Parts I and II are historical data assessed by an examiner and are designed to rate mentation, behaviour and mood; Part III is done as a motor examination at the time of a visit. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II and III (Range: 0 to 236). Higher score indicative of worse outcome.	Baseline; Week 104

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Motor signs of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score in the OFF medication state from baseline to Week 104.	This component of the MDS-UPDRS scale (Section III) assesses the motor signs of PD and will involve a motor examination at the time of a visit. The score ranges from 0 to 132. Higher score is indicative of worse outcome.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Motor complications of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV score in the ON medication state from baseline to Week 104.	This component of the MDS-UPDRS scale (Section IV) assesses two motor complications, dyskinesias and motor fluctuations using historical and objective information. The score ranges from 0 to 24. Higher score indicative of worse outcome.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The non-motor impact of PD on patients using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I score in the ON medication state baseline to Week 104.	This component of the MDS-UPDRS scale (Section I) assesses the non-motor impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 24. Higher score indicative of worse outcome.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The motor aspect impact of PD of patients experiences on daily living using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II score in the ON medication state from baseline to Week 104.	This component of the MDS-UPDRS scale (Section II) assesses the motor aspect impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 52. Higher score indicative of worse outcome.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Cognitive impairment using the Montreal Cognitive Assessment from baseline to Week 104.	A 30 question test which assesses mild cognitive impairment by checking participant orientation, short-term memory, executive function, language, abstraction, naming of animals, attention and a clock drawing test. Maximum score= 30. Lower scores indicative of worse outcome.	At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Patient reported measure of health status and quality of life using the Parkinson's disease 39 item Quality of Life questionnaire from baseline to Week 104.	A questionnaire which assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living. The 39 item questionnaire offers a patient reported measure of health status and quality of life and is the most frequently used disease-specific health status measure. Maximum score = 156. Higher score= worse outcome.	At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Symptom improvement from baseline to Week 104 using the Patient Global Impression of Change from baseline to Week 104.	A 1 item questionnaire which asks a participant to report their own impression of change in their clinical status. Maximum score = 7. Higher score= worse outcome.	At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Quality-of-Life outcome differences between the two treatment groups from baseline to Week 104, as measured by the descriptive system for health-related quality of life, EQ-5D-5L.	The EQ-5D-5L is a participant self-reported questionnaire which evaluates the generic quality of life at the time of completion. It comprises of one question for each of the five dimensions ;no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. An Visual Analogue Scale is also used and is a scale measured from 0 -100 scale where patients are asked to indicate their overall health on the day of questionnaire completion. Maximum score = 100. Lower score = worse outcome.	At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Non-motor symptoms of PD from baseline to Week 104 , as measured by the Non-Motor Symptoms Scale.	The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. Maximum score = 360. Higher score = worse outcome.	At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
PD progression measured using Parkinson's Disease Comprehensive Response from baseline to Week 104	A composite approach integrating three standard outcome measures PDCORE = (1 × change in OFF state motor score) + (2 × change in OFF state ADL score) - (10 × change in total good-quality ON time per day). Higher score = worse outcome.	At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Assessment of postural instability and falls from baseline to Week 104 using the Dresden Falls Questionnaire.	A self-reported assessment of falls, near falls, fear of falling, fall-related injuries, and causes of falls for patients with Parkinson's disease. Maximum score = 12. Higher score = worse outcome.	At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Symptom severity, treatment response and the efficacy of treatment from baseline to Week 104 using the Clinical Global Impression of symptom severity and improvement scales.	Research team assessment. The CGI has two components-the CGI-Severity, which rates illness severity, and the CGI-Improvement, which rates change from the initiation (baseline) of treatment. Maximum score = 14. Higher score = worse outcome.	At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in pulse (bpm) from baseline to Week 104	Vital signs	At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in blood pressure (mmHg) from baseline to Week 104	Vital signs	At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in temperature (°) from baseline to Week 104	Vital signs	At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in respiratory rate (breaths per minute)from baseline to Week 104	Vital signs	At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Body Mass Index (weight and height will be combined to report BMI in kg/m^2) from baseline to Week 104	Vital signs	At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Red Blood Cell Count (10^12/L) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haemoglobin (g/dL) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Haematocrit (%) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Platelets (10^9/L) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in White Blood Cell Count (10^9/L) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Neutrophils (10^9/L) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Eosinophils (10^9/L) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Basophils (10^9/L) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Lymphocytes (10^9/L) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Monocytes (10^9/L) from baseline to Week 104	Standard diagnostic laboratory test (Full Blood Count)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Urea (mmol/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Sodium (mmol/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Potassium (mmol/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Creatinine (µmol/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Total Bilirubin (µmol/L)from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alkaline phosphatase (IU/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Alanine transaminase (IU/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Aspartate Aminotransferase (IU/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Uric Acid (mg/dL) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Bicarbonate (mmol/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by changes in Chloride (mmol/L) from baseline to Week 104	Standard diagnostic laboratory test (Biochemistry)	At Screening; Week 20; Week 40; Week 60; Week 80; Week 104
Safety and tolerability of ambroxol hydrochloride as indicated by the occurrence / severity of treatment related Adverse Events assessed by CTCAE v5.0 from baseline to Week 104	Number of participants with treatment related adverse events assessed by CTCAE v5.0 from baseline to Week 104.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) tremor score from baseline to Week 104.	The tremor components of the MDS-UPDRS scale	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) non-tremor score from baseline to Week 104.	The non-tremor components of the MDS-UPDRS scale	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.
Time to initiation of rescue medication	Length of time until initiation of rescue medication from baseline to Week 104.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Change in levodopa equivalent dose at 104 weeks	Calculated levodopa equivalent dose from baseline to Week 104.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
The association between ambroxol, the glucocerebrosidase enzyme and other proteins associated with the development of PD measured by glucocerebrosidase enzyme activity and other protein markers in blood and cerebrospinal fluid (CSF) samples.	There is evidence of a reciprocal relationship between PD development and glucocerebrosidase enzyme activity. Testing levels of glucocerebrosidase enzyme activity in blood and CSF samples is used to assess the ability of ambroxol to modulate glucocerebrosidase enzyme activity.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
The association between ambroxol and glycerylceramide, neurofilament light chain and lipid levels in cerebrospinal fluid (CSF) samples from baseline to Week 104.	Testing levels of glycerylceramide, neurofilament light chain and lipid levels in CSF samples is used to access the ability of ambroxol to modulate their activity.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Affect of GBA status on all measurement outcomes for both treatment arms from baseline to Week 104.	Analysis of all outcome data from both treatment arms in comparison to GBA status at screening.	Baseline and Week 104
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- IV score from baseline to Week 130.	The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104 and week 130. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II, III and IV. Higher score indicative of worse outcome.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104; Week 130
The association between ambroxol and alpha-synuclein levels in blood and cerebrospinal fluid (CSF) samples from baseline to Week 104.	Alpha-synuclein is a key protein involved in Parkinson's disease (PD) pathology. Testing levels of Alpha-synuclein in blood and CSF samples is used to access the ability of ambroxol to modulate Alpha-synuclein activity.	Baseline; Week 20; Week 40; Week 60; Week 80; Week 104
Comparison of change in the gut microbiome composition from baseline to Week 104.	Faecal samples will be collected to analyse the gut microbiome.	Baseline and Week 104.
Comparison of The Smell Identification Test [UPSIT] score change from baseline to week 104.	Smell identification to test the function of an individual's olfactory system.	Baseline and Week 104.

Collaborators and Investigators

• Sponsor: University College, London
• Investigators: Principal Investigator: Anthony Schapira, University College, London

Publications and helpful links

Helpful Links

• ASPro-PD Trial Website

Study record dates

Study Major Dates

• Study Start (Actual): February 25, 2025
• Primary Completion (Estimated): February 1, 2029
• Study Completion (Estimated): September 1, 2029

Study Registration Dates

• First Submitted: February 16, 2023
• First Submitted That Met QC Criteria: March 9, 2023
• First Posted (Actual): March 21, 2023

Study Record Updates

• Last Update Posted (Actual): May 1, 2025
• Last Update Submitted That Met QC Criteria: April 30, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: Nervous System Diseases; Movement Disorders; Central Nervous System Diseases; Neurodegenerative Diseases; Brain Diseases; Synucleinopathies; Parkinsonian Disorders; Basal Ganglia Diseases; Ambroxol
• Additional Relevant MeSH Terms: Synucleinopathies; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurodegenerative Diseases; Movement Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Parkinson Disease; Expectorants; Respiratory System Agents; Ambroxol
• Other Study ID Numbers: CCTU/2020/365

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No